info@marketresearchfuture.com   ūüďě  +1 (855) 661-4441(US)   ūüďě  +44 1720 412 167(UK)
Certified Global Research Member
Isomar fd.webp Wcrc 57.webp
Key Questions Answered
  • Global Market Outlook
  • In-depth analysis of global and regional trends
  • Analyze and identify the major players in the market, their market share, key developments, etc.
  • To understand the capability of the major players based on products offered, financials, and strategies.
  • Identify disrupting products, companies, and trends.
  • To identify opportunities in the market.
  • Analyze the key challenges in the market.
  • Analyze the regional penetration of players, products, and services in the market.
  • Comparison of major players financial performance.
  • Evaluate strategies adopted by major players.
  • Recommendations
Why Choose Market Research Future?
  • Vigorous research methodologies for specific market.
  • Knowledge partners across the globe
  • Large network of partner consultants.
  • Ever-increasing/ Escalating data base with quarterly monitoring of various markets
  • Trusted by fortune 500 companies/startups/ universities/organizations
  • Large database of 5000+ markets reports.
  • Effective and prompt pre- and post-sales support.

Pulmonary Edema Market Research Report Information: By Type (Cardiogenic Edema), Diagnosis (Blood Tests, Imaging), Treatment (Morphine, Suction Catheter), End Users (Hospitals & Clinics, Academic Institutes, Retail Pharmacies) - Forecast Till 2032


ID: MRFR/Pharma/4158-HCR | 90 Pages | Author: Rahul Gotadki| July 2024

Global Pulmonary Edema Market Overview


The Pulmonary Edema Market Size was valued at USD 12.08 Billion in 2023. The Global Pulmonary Edema industry is projected to grow from USD 13.40 Billion in 2024 to USD 28.21 Billion by 2032, exhibiting a compound annual growth rate (CAGR) of 8.63% during the forecast period (2024 - 2032).


Pulmonary edema or lung congestion refers to a medical condition distinguished by the presence of unnecessary fluid in the lungs. This may affect the trade of gases causing respiratory failures. Several non-cardiac and cardiac conditions are linked with the disease that appears when the heart cannot fulfill the body's demands. This can be explained by congestive heart failure. Wheezing, fatigue, palpitations, dyspnea, and others are popular symptoms of pulmonary edema. The treatment process for the disease differs from the cause. However, supplemental medications and oxygen elevate the backgrounds for most treatment methods. The global market for pulmonary edema has registered a major spike in the growth rate in the last few years. The market's growth is primarily attributed to the growing prevalence of pulmonary edema and diseases such as pancreatitis, heart diseases, and kidney failure across the globe. In addition, the growing geriatric population worldwide is also anticipated to boost the market's growth in the coming years. On the other hand, the factors such as low per capita healthcare expenditure, lack of awareness, and unaffordability for treatment are estimated to hamper the market's growth.


Segmentation


The pulmonary edema market is segmented on the basis of type, diagnosis, treatment, and end user.


On the basis of the type, the pulmonary edema market is segmented into cardiogenic edema, cardiogenic edema, and others.


On the basis of the diagnosis, the pulmonary edema market is categorized into blood tests, imaging, and others. The blood tests segment is sub-segmented into b-type natriuretic peptide (BNP), blood count test, kidney function test, and others. The imaging segment is sub-segmented into chest x-ray, electrocardiogram, echocardiogram, transesophageal echocardiography, pulse oximetry, and others. On the basis of the treatment, the pulmonary edema market is segmented into preload reducers, morphine, suction catheter, and others. The preload reducers segment is sub-segmented into nitroglycerin, diuretics, and others. On the basis of the end users, the pulmonary edema marketis segmented into hospitals & clinics, academic institutes, retail pharmacies, and others.


Regional Analysis


America dominates the pulmonary edema market owing to a well-developed healthcare sector and high per capita healthcare expenditure. Moreover, the presence of developed economies like U.S. and Canada and global players such as Pfizer Inc., Edwards Lifesciences Corporation, ARGON MEDICAL, and others within the regional boundaries of the Americas fuels the pulmonary edema market growth.


Europe is the second largest pulmonary edema market and is followed by the Asia Pacific due to the availability of funds for research, the presence of developed economies like France, Italy, and Germany within the region. Additionally, growing geriatric population in Europe further boosts the pulmonary edema market growth. 


The Asia Pacific is the fastest growing region in the market due to the presence of developing economies like India and China within the region. Moreover, rising healthcare expenditure and favorable government policies drive the market growth. According to the Indian Brand Equity Foundation in 2018, Indian healthcare is the largest sector in terms of revenue & employment. Moreover, the industry is expected to grow at an exponential rate owing to increasing expenditure by the public and private players.


The Middle East & Africa holds the least share of the pulmonary edema market.  Presence of poor economies, especially within in the African region makes the market to lag. Middle East accounts for the majority of the market share in the Middle East & Africa region due to a huge healthcare expenditure by the presence of the developed economies such as Saudi Arabia, Kuwait, and Qatar within the region.


Some of the key players in the Pulmonary Edema Market


Pfizer Inc. (U.S.), ARGON MEDICAL (U.S.), Edwards Lifesciences Corporation (U.S.), BD (U.S.), Alcaliber S.A. (Spain), Lupin Pharmaceuticals, Inc. (India), Vitaltec Corporation (China), Medtronic (U.S.), Koninklijke Philips N.V. (The Netherlands), Siemens Healthcare GmbH (Germany), Hitachi Medical Corporation (U.S.), and Canon Medical Systems Corporation (Japan).
Recent Development

In February 2022- AstraZeneca, a British-Swedish multinational pharmaceutical and biotechnology company, is sticking out with an animated fantasyland theme for its Breztri TV ad but utilizes a blast from the past to illustrate a brighter future. The primary phase asks patients to "Get Real" concerning their chronic obstructive pulmonary disease (COPD) and flare-ups, highlighting that improved breathing doesn't make everything "fun and nice."
In January 2022- a prominent player in the development of gas exchange monitoring technology, MediPines Corporation, has announced for complete national distribution throughout the United States for its exclusive AGM100 device, first FDA-cleared, non-invasive pulmonary gas exchange analyzer system across the globe.

Intended Audience



  • Pharmaceutical companies

  • Biotechnological institutes

  • Research and Development (R&D) Companies

  • Medical Research Laboratories

  • Market Research and Consulting Service Providers


Report Attribute/Metric Details
  Market Size   28.21 Billion
  CAGR   8.62% (2024-2032)
  Base Year   2023
  Forecast Period   2024-2032
  Historical Data   2020
  Forecast Units   Value (USD Billion)
  Report Coverage   Revenue Forecast, Competitive Landscape, Growth Factors, and Trends
  Segments Covered   Type, Diagnosis, Treatment, and End user
  Geographies Covered   North America, Europe, Asia-Pacific, and Rest of the World (RoW)
  Key Vendors   Pfizer Inc. (U.S.), ARGON MEDICAL (U.S.), Edwards Lifesciences Corporation (U.S.), BD (U.S.), Alcaliber S.A. (Spain), Lupin Pharmaceuticals, Inc. (India), Vitaltec Corporation (China), Medtronic (U.S.), Koninklijke Philips N.V. (The Netherlands), Siemens Healthcare GmbH (Germany), Hitachi Medical Corporation (U.S.), and Canon Medical Systems Corporation (Japan)
  Key Market Opportunities   New product launches and R&D Amongst major key Players
  Key Market Drivers   Increasing prevalence of pulmonary edema and diseases


Frequently Asked Questions (FAQ) :

Pulmonary Edema Market is a condition wherein excessive fluid gathers in the lungs, making respiration difficult.

The market is expected to exhibit a strong 8.62% CAGR over the forecast period till 2032.

The growing prevalence of cardiovascular conditions is the major driver for the pulmonary edema market.

Americas dominates the global pulmonary edema market, followed by Europe.

Leading players in the pulmonary edema market include Edwards, Argon Medical, and Pfizer, among others.

Leading companies partner with us for data-driven Insights
client_1 client_2 client_3 client_4 client_5 client_6 client_7 client_8 client_9 client_10
Kindly complete the form below to receive a free sample of this Report
Please fill in Business Email for Quick Response

We do not share your information with anyone. However, we may send you emails based on your report interest from time to time. You may contact us at any time to opt-out.

Purchase Option
Single User $ 4,950
Multiuser License $ 5,950
Enterprise User $ 7,250
Compare Licenses
Tailored for You
  • Dedicated Research on any specifics segment or region.
  • Focused Research on specific players in the market.
  • Custom Report based only on your requirements.
  • Flexibility to add or subtract any chapter in the study.
  • Historic data from 2014 and forecasts outlook till 2040.
  • Flexibility of providing data/insights in formats (PDF, PPT, Excel).
  • Provide cross segmentation in applicable scenario/markets.